MK-677 (Ibutamoren) and Sildenafil Interaction: What Clinicians and Patients Need to Know

What Is MK-677 (Ibutamoren) and Why Do People Combine It with Sildenafil?

MK-677 is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) secretion and raises IGF-1 levels without suppressing the hypothalamic-pituitary axis. Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Men pursuing body-composition protocols sometimes use both simultaneously, one for lean mass and recovery, the other for sexual function. That overlap creates a real clinical question even though no dedicated interaction trial exists.

Why MK-677 Is Used

Researchers initially developed MK-677 to treat GH deficiency, muscle wasting, and osteoporosis. A 2-year randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=65 healthy older adults) found that oral ibutamoren mesylate 25 mg daily produced sustained increases in serum IGF-1 and GH without stimulating cortisol 1. Despite that evidence, MK-677 remains unapproved by the FDA for any indication and is classified as a research chemical 2.

Why Sildenafil Is Prescribed

The FDA approved sildenafil (Viagra, 25 to 100 mg as needed) for erectile dysfunction in 1998, and the same molecule at a fixed 20 mg three-times-daily dose (Revatio) for PAH 3. Its mechanism is inhibition of PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. Elevated cGMP relaxes smooth muscle and dilates blood vessels, lowering both systemic and pulmonary vascular resistance.

The Overlap Population

Among men aged 35 to 65 pursuing hormone optimization protocols, simultaneous use of GH secretagogues and PDE5 inhibitors is common enough that telehealth providers report seeing it weekly. No published epidemiological study quantifies exact co-use prevalence, but anecdotal forum data and clinical observation align on this demographic.

Pharmacokinetic Interaction: CYP3A4, P-glycoprotein, and What We Actually Know

The first question in any drug interaction analysis is whether two compounds compete for the same metabolic or transport pathway. Here the data are asymmetric: sildenafil's pharmacokinetics are well-characterized; MK-677's are not published in full detail.

Sildenafil's Metabolic Profile

Sildenafil is primarily metabolized by hepatic CYP3A4 (major) and CYP2C9 (minor) 3. Strong CYP3A4 inhibitors (ritonavir, ketoconazole) increase sildenafil AUC by up to 11-fold, requiring dose reduction to 25 mg. Strong inducers (rifampin) reduce sildenafil AUC by 63% 3. Sildenafil's half-life is approximately 4 hours, and its active metabolite N-desmethylsildenafil contributes roughly 20% of pharmacological activity.

MK-677's Metabolic Profile

Published pharmacokinetic data on MK-677 in humans are limited. A phase I study of ibutamoren mesylate (MK-677) reported an oral bioavailability of approximately 60 to 70% and a terminal half-life of approximately 4 to 6 hours in young healthy adults 4. Detailed CYP induction or inhibition data for MK-677 have not been published in peer-reviewed journals. Preclinical receptor-binding studies suggest MK-677 acts primarily through the GHSR-1a receptor rather than through direct CYP modulation 5. Because no strong human CYP interaction data exist, a direct pharmacokinetic drug-drug interaction between MK-677 and sildenafil cannot be confirmed or excluded from primary literature alone.

P-glycoprotein Considerations

Sildenafil is a weak P-glycoprotein (P-gp) substrate. MK-677's P-gp status is not publicly characterized. No currently available DDI database lists a transporter-based interaction between these two compounds.

Pharmacodynamic Interaction: Where the Real Risk Lives

The more clinically meaningful concern is pharmacodynamic overlap, specifically the combined effect on blood pressure, fluid balance, and glucose metabolism.

Blood Pressure and Cardiovascular Hemodynamics

Sildenafil produces a mean maximum decrease in supine systolic blood pressure of 8.4 mmHg and 5.5 mmHg diastolic after a single 100 mg dose in healthy volunteers 3. This drop is amplified substantially when sildenafil is combined with nitrates, alcohol, alpha-blockers, or antihypertensive agents. The FDA label for Viagra carries an explicit contraindication against use with any nitrate in any form 3.

MK-677 raises GH and IGF-1. GH has direct vasodilatory effects through nitric oxide pathways. A placebo-controlled study in GH-deficient adults found that GH replacement reduced total vascular resistance and increased cardiac output within 8 weeks 6. Raised IGF-1 also correlates with reduced arterial stiffness 7. Combining an agent that raises GH/IGF-1 with a vasodilatory PDE5 inhibitor could theoretically produce additive blood pressure reduction, though no clinical trial has measured this combination directly.

Fluid Retention and Edema

MK-677 commonly causes sodium and water retention mediated through GH-stimulated renal sodium reabsorption. In the Nass et al. 2-year trial (N=65), peripheral edema occurred in 19% of the ibutamoren group versus 3% of placebo 8. Patients already at risk for heart failure or those taking sildenafil for PAH (where right ventricular function may already be compromised) face a compounded fluid-management challenge when adding MK-677.

Glucose and Insulin Sensitivity

GH is inherently counter-regulatory to insulin. The same Nass et al. Trial reported fasting blood glucose increases averaging 0.3 mmol/L and a statistically significant rise in HbA1c in the ibutamoren group 8. Emerging evidence suggests sildenafil may actually improve insulin sensitivity in some populations. A randomized crossover study (N=18) published in Diabetes Care found that sildenafil 25 mg three times daily for 3 months improved insulin sensitivity index by 23% in obese men with prediabetes 9. If MK-677 raises glucose and sildenafil partially offsets that, the net metabolic direction remains unpredictable without individual monitoring.

Severity Classification and Clinical Risk Stratification

No established DDI database (Lexicomp, Micromedex, Clinical Pharmacology) currently lists a formal severity rating for MK-677 plus sildenafil, because MK-677 is not an approved drug and therefore is not included in standard drug monographs. Severity must therefore be inferred from mechanistic analysis.

Low-Risk Profile Patients

A healthy male aged 30 to 45 with normal blood pressure, no cardiac history, no nitrate use, and no antihypertensive medications who takes MK-677 25 mg nightly and sildenafil 50 mg as needed faces a relatively low but not zero pharmacodynamic interaction risk. The primary concern is additive vasodilation from GH-mediated nitric oxide effects plus PDE5 inhibition.

Higher-Risk Profile Patients

Risk escalates meaningfully in patients with any of the following: baseline systolic blood pressure below 100 mmHg, concurrent alpha-blocker use, concurrent antihypertensive therapy, active cardiac disease, PAH (where the sildenafil dose is 20 mg three times daily), or pre-existing peripheral edema. In these groups, the combination may need to be avoided or managed with blood pressure telemetry.

Absolute Contraindications That Supersede This Discussion

Sildenafil is absolutely contraindicated with nitrates and with riociguat (a guanylate cyclase stimulator). Any patient using these agents must not take sildenafil regardless of MK-677 status 3.

Monitoring Protocol for Concurrent Use

Because no formal guideline addresses this specific combination, the HealthRX medical team developed the following monitoring framework based on the individual drug labels, published pharmacology, and established GH-replacement monitoring standards from the Endocrine Society 10.

Baseline Assessments Before Starting Both Agents

Clinicians should obtain the following before initiating concurrent use:

• Seated blood pressure (two readings, 5 minutes apart)
• Fasting glucose and HbA1c
• Serum IGF-1 (to establish pre-treatment baseline)
• BMP or CMP to assess renal function and electrolytes
• Resting ECG if age exceeds 50 or cardiac risk factors are present
• Medication reconciliation focused on nitrates, alpha-blockers, and antihypertensives

On-Treatment Monitoring Schedule

At 4 weeks: repeat blood pressure, fasting glucose, and assess for peripheral edema.

At 8 to 12 weeks: repeat IGF-1, HbA1c, and blood pressure. The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency in adults recommends targeting IGF-1 in the age- and sex-adjusted normal range during GH or GH-secretagogue therapy 10. Patients should report any lightheadedness, chest discomfort, or syncope immediately.

At 6 months: full metabolic panel, repeat IGF-1, and blood pressure. Consider 24-hour ambulatory blood pressure monitoring if home readings are variable.

Patient Counseling Points

Patients should be told to avoid sildenafil within 4 hours of any nitrate-containing substance, including recreational amyl nitrite ("poppers"). They should measure blood pressure at home before the first sildenafil dose when co-administering with MK-677, targeting a pre-dose systolic above 90 mmHg. If dizziness occurs after sildenafil, they should sit or lie down and avoid driving.

Dose Considerations

MK-677 Dosing Context

The doses studied in published trials range from 10 mg to 25 mg orally once daily. The Copinschi et al. Study (N=32 obese males) used 25 mg daily and demonstrated significant GH pulse amplification without pituitary axis suppression 11. Higher doses above 25 mg are not supported by published human data and increase the likelihood of fluid retention and glucose dysregulation.

Sildenafil Dosing Context

The approved ED dose range is 25 mg to 100 mg as needed, no more than once daily. The FDA label recommends starting at 25 mg in patients on CYP3A4 inhibitors or with hepatic impairment 3. In patients co-administering MK-677 (an agent with uncertain CYP effects), a conservative starting dose of 25 to 50 mg is reasonable until individual tolerability is established.

Timing Separation

MK-677 is typically taken at bedtime because it amplifies the nocturnal GH pulse. Sildenafil for ED is taken 30 to 60 minutes before sexual activity. The 4- to 6-hour half-lives of both compounds mean their pharmacologically active windows may overlap when sildenafil is used in the evening. Taking sildenafil in the late afternoon (4 to 6 hours before MK-677 administration) could minimize the window of simultaneous peak plasma concentrations, though this remains an unvalidated strategy.

What the Evidence Gap Means for Clinical Decision-Making

The absence of a published, controlled pharmacokinetic interaction study between MK-677 and sildenafil is the defining limitation here. MK-677's unregulated status means it will not receive FDA-mandated DDI studies. The Endocrine Society's 2019 Clinical Practice Guideline on GHRH and GH secretagogues notes that safety data for newer secretagogues remain insufficient for routine clinical endorsement outside of investigational protocols 12.

Sildenafil's label explicitly states: "The safety of VIAGRA is unknown in patients with... Severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), uncontrolled hypertension (blood pressure > 170/110 mmHg), recent history of stroke, life-threatening arrhythmia, myocardial infarction..." 3. These contraindications apply regardless of what other compounds the patient uses.

Clinicians prescribing or counseling patients on this combination should document their risk-benefit reasoning, confirm the absence of absolute contraindications, and set a clear monitoring schedule as outlined above.

Real-World Context: Who Is Asking This Question

The population most likely to combine MK-677 and sildenafil is males aged 35 to 60 pursuing hormone optimization through telehealth or performance medicine providers. Many are self-sourcing MK-677 online. A 2020 analysis of WADA-prohibited substance seizures found GH secretagogues including ibutamoren in 14% of sampled supplement products, sometimes without label disclosure 13. Patients may not volunteer MK-677 use to their prescribing physician, making medication reconciliation at every visit critical.

The FDA has issued warning letters to companies marketing ibutamoren and other SARMs as dietary supplements, affirming that such products are illegal when sold for human consumption 14. Prescribers should counsel patients on this regulatory status and document that discussion.

Summary of Interaction Profile

The table below synthesizes the interaction profile across the four standard DDI domains.

| Domain | MK-677 | Sildenafil | Combined Risk | |---|---|---|---| | CYP/PK | Not fully characterized | CYP3A4, CYP2C9 substrate | Cannot exclude interaction; low suspicion | | Blood pressure | GH/IGF-1 vasodilation via NO | PDE5 inhibition, 8 mmHg systolic drop | Additive vasodilation possible | | Fluid balance | Na/water retention (19% edema rate) | Minimal direct effect | Additive in susceptible patients | | Glucose | Raises fasting glucose | May improve insulin sensitivity | Net effect unpredictable; monitor HbA1c |